COLLPLANT BIOTECH. IS-01 Net Assets
COLLPLANT BIOTECH. IS-01 net assets. Based on the latest financial reports, COLLPLANT BIOTECH. IS-01 (CPT) has net assets worth €4.89 Million EUR (≈ $5.71 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€9.18 Million ≈ $10.74 Million USD) and total liabilities (€4.30 Million ≈ $5.02 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is COLLPLANT BIOTECH. IS-01 growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.89 Million |
| % of Total Assets | 53.21% |
| Annual Growth Rate | -39.41% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 17.65 |
Net Assets of COLLPLANT BIOTECH. IS-01 (2021–2025)
Net assets of COLLPLANT BIOTECH. IS-01 from 2021 to 2025. This chart illustrates how COLLPLANT BIOTECH. IS-01's net assets have evolved over time, based on quarterly financial data. See CPT equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for COLLPLANT BIOTECH. IS-01 (2021–2025)
The table below shows the annual net assets of COLLPLANT BIOTECH. IS-01 from 2021 to 2025. For live market cap and overall valuation, see how much is COLLPLANT BIOTECH. IS-01 worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €6.08 Million ≈ $7.11 Million |
-54.84% |
| 2024-12-31 | €13.46 Million ≈ $15.74 Million |
-52.49% |
| 2023-12-31 | €28.34 Million ≈ $33.13 Million |
-12.21% |
| 2022-12-31 | €32.28 Million ≈ $37.74 Million |
-28.46% |
| 2021-12-31 | €45.12 Million ≈ $52.75 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to COLLPLANT BIOTECH. IS-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5204200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
COLLPLANT BIOTECH. IS-01 Net Assets Breakdown (December 2025)
COLLPLANT BIOTECH. IS-01 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €130.92 Million | 2152.94% |
| Total Equity | €6.08 Million | 100.00% |
COLLPLANT BIOTECH. IS-01 Competitors by Market Cap
The table below lists competitors of COLLPLANT BIOTECH. IS-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kalgoorlie Gold Mining Ltd
AU:KAL
|
$5.48 Million |
|
SenesTech Inc
NASDAQ:SNES
|
$5.48 Million |
|
Pacific Empire Minerals Corp
F:1YK
|
$5.49 Million |
|
TV Thunder Public Company Limited
BK:TVT
|
$5.49 Million |
|
MKDWELL Tech Inc. Ordinary Share
NASDAQ:MKDW
|
$5.48 Million |
|
Philly Shipyard ASA
OL:PHLY
|
$5.48 Million |
|
Fidelity Minerals Corp
V:FMN
|
$5.48 Million |
|
Elkop SA
WAR:EKP
|
$5.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in COLLPLANT BIOTECH. IS-01's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,465,000 to 6,081,000, a change of -7,384,000 (-54.8%).
- Net loss of 11,489,000 reduced equity.
- New share issuances of 3,102,000 increased equity.
- Other factors increased equity by 1,003,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-11.49 Million | -188.93% |
| Share Issuances | €3.10 Million | +51.01% |
| Other Changes | €1.00 Million | +16.49% |
| Total Change | €- | -54.84% |
Book Value vs Market Value Analysis
This analysis compares COLLPLANT BIOTECH. IS-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.76x to 6.68x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.19 | €3.18 | x |
| 2022-12-31 | €2.89 | €3.18 | x |
| 2023-12-31 | €2.47 | €3.18 | x |
| 2024-12-31 | €1.18 | €3.18 | x |
| 2025-12-31 | €0.48 | €3.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently COLLPLANT BIOTECH. IS-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -188.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -484.56%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.77x
- Recent ROE (-188.93%) is below the historical average (-77.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.53% | 1.52% | 0.31x | 1.14x | €-4.28 Million |
| 2022 | -52.43% | -5660.54% | 0.01x | 1.17x | €-20.15 Million |
| 2023 | -24.77% | -64.05% | 0.32x | 1.20x | €-9.85 Million |
| 2024 | -123.35% | -3225.05% | 0.03x | 1.39x | €-17.96 Million |
| 2025 | -188.93% | -484.56% | 0.22x | 1.77x | €-12.10 Million |
Industry Comparison
This section compares COLLPLANT BIOTECH. IS-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| COLLPLANT BIOTECH. IS-01 (CPT) | €4.89 Million | 0.53% | 0.88x | $5.48 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more